Werbung

Pirche AG

 

Pirche is a global technology leader in the application of AI to molecular medicine. Its back end epitope matching technology is redefining compatibility risk assessment as a prerequisite for foreign tissue or allogeneic cells to be accepted by the patient immune system. Pirche‘s front end product is a first and only-in-class proprietary digital diagnostic platform that enables physicians and drug developers to make informed decisions with unprecedented precision. Over 850 leading clinics worldwide are networked with Pirche. Based on its fundamental IP, Pirche is partnering with industry leaders to make a profound impact on the future of healthcare in transplant medicine, autoimmunity and oncology.

 

 

Field of Activity
In transplant medicine, donor-recipient risk assessment to improve organ survival and management of long-term immunosuppression, and in allogeneic cell therapy, design and ‘off-the-shelf’ selection utilizing immune risk profi ling in autoimmunity and oncology
 

Ownership structure and financing

 

German Stock Corporation (Aktiengesellschaft); A-series upcoming; break-even within 24 months expected

 

Partners

 

Werfen, Thermo Fisher Scientifi c, Immucor; 850+ clinics and transplant centers globally

 

Technology The epitope matching technology combines genetic typing with realtime AI-supported immunological simulations of protein interactions. Protected by 25 gratec patents and a proven medical evidence with 70+ peer reviewed publications on more than 200,000 patient cases.

 

Products/services Fully digital diagnostic platform and prediction pipeline based on standard lab data for donor-recipient risk assessment, management of immunosuppression and support of allogeneic cell therapy design and allocation.
 

Unique selling point

 

Pirche‘s patented epitope matching technology transforms transplant medicine and cell therapies driven by exclusive AI algorithms, solid science, and forward-thinking industry partners.

Membership in networks/associations ASHI – American Society for Histocompatibility and Immunogenetics;

TTC – Transplant Therapeutics Consortium; Bio Deutschland

Date of Incorporation/Number of Employees 08/2015/15 employees
 

 

contact:

Thomas Klein
Thomas Klein, Founder & CEO of Pirche
Adresse US: 266 Main Street, Medfield, MA 02052

EU: Nördliche Münchner Straße 27a, 82031 Grünwald, Germany

Telefon Medfield: +1 617 233 7699

Grünwald: +49 89 9090 153 914

E-Mail  Thomas Klein is your contact for spoken communication: thomas.klein@pirche.com
Web-Adresse https://pirche.com
Social Media LinkedIn